We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$124M
Cap. Flow
-$115M
Cap. Flow %
-22.13%
Top 10 Hldgs %
61.71%
Holding
72
New
27
Increased
15
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$12.5M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$11.2M
3
VTRS icon
Viatris
VTRS
+$9.9M
4
ARQL
Arqule Inc
ARQL
+$9.88M
5
TXMD icon
TherapeuticsMD
TXMD
+$8.01M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$19.3M
2
PCRX icon
Pacira BioSciences
PCRX
+$18.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$16.5M
4
CLLS
Cellectis
CLLS
+$15.5M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
51
Madrigal Pharmaceuticals
MDGL
$10.6B
$857K 0.16%
+4,000
New +$1M
KERX
52
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$680K 0.13%
+200,000
New +$721K
MTEM
53
DELISTED
Molecular Templates, Inc.
MTEM
$569K 0.11%
7,040
-4,452
-39% -$341K
AKRX
54
DELISTED
Akorn Inc
AKRX
$454K 0.09%
35,000
-234,503
-87% -$3.85M
IMDZ
55
DELISTED
Immune Design Corp.
IMDZ
$146K 0.03%
+42,304
New +$159K
VCNX
56
DELISTED
Vaccinex, Inc. Common Stock
VCNX
$124K 0.02%
+81
New +$167K
CLLS
57
Cellectis
CLLS
$269M
– –
-548,212
Closed -$15.5M
CORT icon
58
Corcept Therapeutics
CORT
$12.4B
– –
-335,177
Closed -$5.27M
CRBP icon
59
Corbus Pharmaceuticals
CRBP
$167M
– –
-4,476
Closed -$678K
ESPR
60
DELISTED
Esperion Therapeutics
ESPR
– –
-287,300
Closed -$11.3M
KNSA icon
61
Kiniksa Pharmaceuticals
KNSA
$5.83B
– –
-39,180
Closed -$680K
PCRX icon
62
Pacira BioSciences
PCRX
$1.03B
– –
-566,508
Closed -$18.2M
SAGE
63
DELISTED
Sage Therapeutics
SAGE
– –
-79,080
Closed -$12.4M
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-1,066,914
Closed -$15.2M
SLGL icon
65
Sol-Gel Technologies
SLGL
$270M
– –
-51,537
Closed -$3.98M
TGTX icon
66
CALL
TG Therapeutics
TGTX
$7.98B
– –
-50,000
Closed -$658K
TECX
67
Tectonic Therapeutic
TECX
$522M
– –
-833
Closed -$286K
WHWK
68
Whitehawk Therapeutics
WHWK
$189M
– –
-19,925
Closed -$1.24M
ARAV
69
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-83,333
Closed -$1.01M
SGEN
70
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-102,187
Closed -$6.78M
ALXN
71
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-132,623
Closed -$16.5M
TSRO
72
DELISTED
TESARO, Inc.
TSRO
– –
-433,500
Closed -$19.3M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Nexthera Capital held 72 positions worth $522M, down 19% from $646M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Nexthera Capital withdrew a net $115M in Q3 2018, closing 16 positions and reducing 12 holdings. Its most notable exit was TESARO, Inc., an estimated $19.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 60% a quarter earlier.

Against the trend, Nexthera Capital opened a new position in Bausch Health worth $14M.

  • Nexthera Capital's largest Q3 2018 buy was Bausch Health: 545,500 shares worth $14M.
  • Nexthera Capital added most to Audentes Therapeutics, Inc in Q3 2018, an estimated $11.2M increase.
  • Nexthera Capital's biggest Q3 2018 reduction was AstraZeneca, cutting an estimated $12.4M.
  • Nexthera Capital fully exited TESARO, Inc. in Q3 2018, selling an estimated $19.3M.
  • Nexthera Capital's ten largest holdings make up 62% of its $522M portfolio in Q3 2018.
  • Nexthera Capital opened 27 new positions and closed 16 in Q3 2018.
  • Nexthera Capital's portfolio value fell 19% quarter-over-quarter to $522M.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.